ArticleJournal of microbiology and biotechnology2024
Molecular Characterization and Interaction between Human VEGF-D and VEGFR-3.
Article in Journal of microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis and lymphangiogenesis are some of the routes that cause metastasis. Vascular Endothelial Growth Factors (VEGFs) stimulate angiogenesis and lymphangiogenesis through VEGF receptors. Especially, VEGF-D and its receptor, VEGFR-3, play a pivotal role in regulating cellular processes such as survival, proliferation, and migration, thereby influencing lymphangiogenesis. The aim of this research is to clarify the molecular characteristics of VEGF-D and VEGFR-3 proteins and identify the key residues that are essential for the interaction between VEGF-D and VEGFR-3. Experiments, including size exclusion chromatography and GST pull-down assay analysis, reveal that specific residues, particularly D103 and Q110, are essential for VEGF-D/VEGFR-3 binding. Mutations in these residues induce structural alterations, resulting in reduced binding affinity and impaired activation of VEGFR-3. Moreover, this study suggests that a synthesized peptide, designed based on key residues of VEGF-D involved in binding to VEGFR-3, may act as a metastasis suppressor by competitively inhibiting the interaction between VEGF-D and VEGFR-3. Understanding these molecular interactions is expected to have significant potential to develop therapeutic peptides that can inhibit cancer cell-induced lymphangiogenesis and resolve metastasis via lymphangiogenesis across various cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.